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Tuberculosis is a communicable disease with public health implications and effective treatment is essential for 
control of the disease and prevention of the emergence of drug resistant strains. Drug therapy for this disease is well 
established and discussion now surrounds frequency of administration, duration of treatment and methods of 
improving compliance. Directly observed intermittent therapy of tuberculosis is supported by the World Health 
Authority and has become the standard of care in the U.S.A. Available dosage guidelines for directly observed 
therapy are only supported by limited data. A literature review of recent studies with clinical outcome measures was 
conducted. Following this review evidence based guidelines have been produced. 
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Introduction 
Tuberculosis (TB) is a communicable disease that has 
troubled physicians for thousands of years and has been a 
leading cause of death in Europe and the U.S.A. for 
centuries (1). The introduction of effective antibiotics and 
public health strategies during the 20th century should have 
resulted in tuberculosis becoming a disease of the past. 
However, the number of cases of tuberculosis, in both 
developed countries and world-wide, is rising. 
The range of antibiotics available to treat Mycobacteviuln 
tuberculosis infections is long established (1,2) and the 
discussion amongst physicians no longer surrounds which 
drugs to use, but the frequency and duration with which to 
use them. Originally treatment courses were for 2 years, but 
it is now accepted that a six month rifamycin containing 
regimen is effective (3). However, this still requires patients 
to take several tablets on a daily basis for a long time and 
for the greatest part of the course they have no symptoms. 
Non-compliance with medication for asymptomatic, 
chronic disease has been demonstrated to be in the region 
of 30&50% (4,5,6). In tuberculosis this can result in both 
personal and public health risks and has been associated 
with the emergence of multi-drug resistant tuberculosis 
(1,7,8). 
Improving compliance is an important aspect of tuber- 
culosis control. This was first highlighted by Wallace Fox, 
in Madras. His initial work demonstrated the efficacy of 
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daily supervized treatment and, later, that intermittent 
therapy, that is administration of anti-tubercular drugs 
twice or three times weekly, was a successful treatment 
option (9). However, when self administered, intermittent 
dosing did not promote compliance, but this is ensured by 
employing directly observed therapy (DOT). Directly 
observed intermittent therapy requires a responsible in- 
dividual, who may be a healthcare professional, to give the 
medication to a patient and to ensure that all doses have 
been taken. This approach has been employed widely in the 
U.S.A., where it has emerged as the standard of care (10). 
The World Health Organisation (WHO) is convinced of 
the benefits to be gained by using DOT (11) although their 
view is not supported by all (12,13). 
Both the British (14) and American (15,16) Thoracic 
Societies have issued guidelines on the dosing regimens that 
should be employed for DOT based largely on ‘best 
practice’ and they provide limited references to support 
the data. 
Following a literature review of recent studies, evidence 
based dosing guidelines have been produced. 
Literature review 
The Iowa Drug Information Service and Medline databases 
were searched using the key words: tuberculosis, pulmonary 
tuberculosis, drug therapy and compliance. Five observa- 
tional studies were identified which had clinical as opposed 
to sociological outcomes. One was discarded on the basis 
that insufficient detail was provided for comparative 
purposes (17). The four studies considered suitable for the 
purposes of this review are summarized in Table 1 (18-21). 
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Caminero et al. evaluated the treatment of 104 patients in Wilkinson et al. (21) reported on a retrospective study of 
Gran Canaria, who were followed for 2 yr (18). Patients the treatment of 109 patients who had undergone DOT in 
were treated with a three-drug regimen, twice weekly for 6 the Kwazulu/Natal region of South Africa. A 95% success 
months. Eighty-seven patients (87%) completed therapy rate is stated. However the limitations to the follow-up 
having negative tests for acid-fast bacilli at the end of the process should be noted. The study population included 
treatment course. The WHO standards (1996) require an transient workers for whom objective follow-up was not 
85% ‘cure’ rate for tuberculosis therapy regimens and possible. Data for these patients is based on third party 
therefore the results of this study are in the appropriate reports of good health. When the objective data is analysed 
range (20). Relapse rate was 3.4% at 2 yr and two patients on an intention to treat basis, the cure rate is 75%. All 
stopped therapy due to adverse drug reactions. patients completed therapy and the relapse rate was 4%. 
Neher et al. reported on the introduction of DOT for the 
treatment of tuberculosis in the Kathmandu valley (19). 
Eight hundred and eighty-six patients were treated with a 
four-drug regimen, three times a week for a period of 9 
months. Streptomycin was substituted for ethambutol if 
side-effects occurred. Patients were followed for 3 yr. 
Therapy failure and relapse rates were 1.6% and 1’3% 
respectively. An 85% cure rate was achieved. 
Discussion 
The dosage regimens for each study were based on varying 
mg kg-’ doses and frequencies. If simplified by calculating 
the total weekly doses for a 60 kg adult, it becomes clear 
that all the studies used similar regimens. 
The Chinese Tuberculosis Control Collaboration re- 
ported on the first 3.5 yr of the DOT programme (20). 
They treated 112 842 patients with a standard four-drug 
regimen on alternate days for 6 months. A fifth drug 
(ethambutol) was added if patients had previously received 
therapy. Over the first 3.5 yr 85.3% of patients were cured 
and a further 2.6% ‘completed treatment’. In those patients 
who have been followed up for 2 yr a 3.2% relapse rate has 
been noted. Failure rates of 5.7% were noted. This study 
represents a huge success for DOT, as previously only 50% 
of patients with TB were cured and the disease was 
responsible for 300 000 deaths in China in 1990. 
It is therefore suggested that doses for directly observed 
therapy for tuberculosis should be based on maximum 
weekly doses and divided into the appropriate frequency 
for the individual patient. Evidence based dosage guidelines 
for directly observed therapy, are shown in Table 2. 
Standard prescription/administration cards are recom- 
mended for clear documentation of therapy. 
Conclusion 
Tuberculosis has public health implications and effective 
treatment is essential for control of spread of disease and 
TABLE 2. Dosage guidelines for DOT of tuberculosis 
Drug Maximum 
weekly 
dose 
Doses for 
twice 
weekly 
regimen 
Doses for 
three x 
weekly 
regimen 
Preparations 
available 
Monitoring 
required 
Isoniazid 
Rifampicin 
Pyrazinamide 
Ethambutol 
Streptomycin 
1.8 g 
1.8 g 
6g 
6g 
3g 
15 mgkg-’ 
max. 900 mg 
10 mg kg-’ 
max. 600 mg 
60 mg kg-’ 
max. 3 g 
50 mgkg-’ 
max. 3 g 
max. 1.5 g 
10 mg kg-’ 
max. 600 mg 
10 mg kg-’ 
max. 600 mg 
40 mg kg-i 
max. 2 g 
30 mg kg-’ 
max. 2 g 
max. 1 g 
Tablets 100 mg 
Syrup 
50 mgml-’ 
Capsules 150 mg 
& 300 mg 
Elixir 100 mgml-’ 
Tablets 500 mg 
Tablets 
400 mg & 100 mg 
IM injection 1 g 
LFT 
FBC 
LFT 
FBC 
LFT 
U&E 
U&E 
Pre- 
treatment 
optical test 
U&E 
Aural test 
Notes: The maximum dose of Rifampicin (600 mg dose-‘) produces plasma concentrations in excess of the mean inhibitory 
concentration for M. tuberculosis. Larger doses are therefore unnecessary and would be associated with an increased incidence 
of side-effects. 
The dosage frequency of streptomycin should be decreased in patients with renal failure; doses should be tailored to the 
individual patient. 
Baseline monitoring should be done before therapy is commenced 
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prevention of the emergence of drug resistant strains. 
Directly observed therapy can increase the rate of course 
completion and appropriate doses of drugs and careful 
documentation should be used. 
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